MAM
KLDO

Martingale Asset Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Martingale Asset Management’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-31,108
Closed -$345K – 1085
2020
Q3 		$345K Sell
31,108
-34,100
-52% -$236K ﹤0.01% 883
2020
Q2 		$485K Buy
+65,208
New +$437K 0.01% 883

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Martingale Asset Management's KLDO Position: Q4 2020 in Review

Martingale Asset Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q4 2020, closing a stake of 31,108 shares — an estimated $345K sold.

Martingale Asset Management first reported a position in KLDO in Q2 2020 and held it in 2 quarters. The position peaked at $485K in Q2 2020. 61 funds tracked by Wall St. Rank hold KLDO as of Q4 2020.

  • Martingale Asset Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Martingale Asset Management sold 31,108 Kaleido Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $345K.
  • Martingale Asset Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Martingale Asset Management's Kaleido Biosciences, Inc. Common Stock position peaked at $485K in Q2 2020.
  • 61 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q4 2020.

Based on Martingale Asset Management's 13F filing for Q4 2020, filed 10 Feb 2021.